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Abstract 
The metabotropic glutamate receptor 5 (mGluR5) is a promising drug target for the treatment 
of schizophrenia. In this study, we compared mGluR5 distribution volume ration (DVR) in 
subjects with schizophrenia and healthy controls. Given our previous findings, we matched 
samples for gender, age, and smoking status. Binding to mGluR5 was determined using 
positron emission tomography and [11C]ABP688, which binds to an allosteric site with high 
selectivity. DVR in the 15 individuals with schizophrenia did not differ from that of the 15 
controls. In both groups, smoking was associated with marked global reductions in mGluR5 
availability (on average 23.8%). In nonsmoking subjects with schizophrenia, there was a 
positive correlation between mGluR5 DVR in the medial orbitofrontal cortex and the use of 
antipsychotic drugs (r = 0.9, p =0.019). Because antipsychotic drugs such as clozapine 
appeared to have indirect effects on mGluR5 signaling, our findings may be clinically 
relevant. They also provide promising leads for elucidating the high comorbidity between 
schizophrenia and tobacco addiction. Low mGluR5 DVR in smokers my represent a risk 
factor for schizophrenia. Alternatively, smoking may counteract the potential upregulation of 
mGluR5 by antipsychotic drugs. 
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1. Introduction 
Current pathogenic models of schizophrenia emphasize hypofunction of the N-methyl-D-
aspartate (NMDA) receptor (Iwata et al., 2015; Kantrowitz and Javitt, 2010). There is 
growing evidence from genetic and animal studies that the metabotropic glutamate receptors 5 
(mGluR5) critically modulates the NMDA receptor (Matosin et al., 2015a). Both receptors co-
localize and share the same scaffolding proteins and show strong functional associations. 
Consequently, mGluR5 has been proposed as an important target for the development of 
antipsychotic drugs (Goff, 2015). In addition, mGluR5 may be directly involved in abnormal 
glutamate signaling in schizophrenia. Genetic deletion of mGluR5 in mice has been shown to 
trigger a schizophrenia-like phenotype with decreased sensorimotor gating and short-term 
spatial memory deficits (Brody et al., 2004; Gray et al., 2009). In rats, treatment with specific 
negative allosteric modulators of mGluR5 leads to similar behavioral deficits, including 
impairments in sensory processing, working memory, and executive function (Vales et al., 
2010; Zou et al., 2007). In humans, the allele frequency distribution of an intragenic 
microsatellite of the mGluR5 gene, GRM5, has been associated with schizophrenia (Devon et 
al., 2001). Several recent genome-wide association studies confirmed the involvement 
putative SNPs in GRM5 (Matosin et al., 2015b). In animal models, administration of 
cannabinoids during adolescence were shown to a reduction in hippocampal mGluR5, which 
was associated with learning deficits (Gleason et al., 2012). In contrast, postmortem studies 
have found only minimal changes in mGluR5 mRNA and mGluR5 protein in schizophrenia 
(Corti et al., 2011; Gupta et al., 2005; Matosin et al., 2013; Volk et al., 2010).  
There is limited evidence for the involvement of mGluR5 in the effects of currently available 
antipsychotic drugs. In mGluR5 knockout mice, chronic administration of clozapine reversed 
sensorimotor gating deficits and abnormal locomotion (Gray et al., 2009). In rats, typical and 
atypical antipsychotics increased mGluR5 mRNA expression (Iasevoli et al., 2010), while 
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other studies did not show changes in mGluR5 binding following treatment with antipsychotic 
drugs, in either animals or human postmortem tissue (Matosin and Newell, 2013). In previous 
studies, we have demonstrated that smoking is associated with a marked global reduction in 
mGluR5 DVR (Akkus et al., 2013; Akkus et al., 2015). This is a potentially relevant finding 
because 60%–90% of individuals with schizophrenia smoke (Chapman et al., 2009), and they 
usually smoke more heavily and experience more difficulty quitting smoking than do smokers 
without schizophrenia (Tidey et al., 2005; Wing et al., 2012). 
This is the first study to assess mGluR5 DVR in subjects with schizophrenia and test for a 
hypothetical difference in DVR between patients and healthy controls. We applied positron 
emission tomography (PET) with the radiolabeled mGluR5 antagonist 3-(6-methyl-pyridin-2-
ylethynyl)-cyclohex-2-enone-O-11C-methyl-oxime ([11C]ABP688) (Ametamey et al., 2007). 
This radiotracer binds to an allosteric site on mGluR5 with high selectivity. Given that age, 
gender, and smoking have been associated with mGluR5 DVR (Akkus et al., 2013; Akkus et 
al., 2015), we matched cases and controls for age, gender, and smoking. Based on preclinical 
and postmortem findings, we hypothesized that lower mGluR5 binding would be present in 
schizophrenia. Based on our previous findings in smokers, we also hypothesized that there 
would be marked global reductions in mGluR5 binding in smokers from both diagnostic 
groups.   
 
2. Methods 
2.1. Participants 
All participants were inpatients or outpatients from the University Hospital of Psychiatry, 
Bern, and were screened using the following tools to assess potential inclusion into the 
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schizophrenia group: an unstructured clinical interview conducted by a psychiatrist; a 
Structured Clinical Interview according to the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition Text Revision; the Positive and Negative Syndrome Scale 
(PANSS); the Bern Psychopathology Scale (BPS); the Beck Anxiety Inventory (BAI); and the 
Beck Depression Inventory (BDI).  
Criteria for exclusion were: additional current psychiatric, medical, or neurological disorders; 
a history of substance dependence; pregnancy; and breastfeeding. A fast magnetic resonance 
imaging scan was performed on each subject and assessed by a radiologist to exclude any 
structural brain pathology. Doses of antipsychotic medications were transformed into 
chlorpromazine equivalents, and estimates of their respective affinity for receptors were 
graded according to radioligand binding assays in post-mortem normal human brain tissue  
(Richelson and Souder, 2000). Receptors of interest (shared receptors where information was 
available) included D2, 5-HT1A, 5HT2A, 5HT2C, alpha adrenergic 1a and 2a, muscarinic 
acetycholine receptor 1, and the histamine receptor H1. Participants were fully informed 
regarding the study purpose and procedures, and provided written informed consent 
(approved by the local ethics committee; Kantonale Ethikkommission Zürich) before any 
study-related procedure was performed. Subjects were nicotine-abstinent for at least one hour 
before acquisition of the PET scan. 
2.2. Positron emission tomography 
As in previous studies, we applied a bolus/infusion protocol (Carson et al., 1993) previously 
evaluated for PET with [11C]ABP688 (Burger et al., 2010). Our method allowed for reliable 
measurement of the relative distribution volume (DVR), and reduced potential bias due to 
arterial blood sampling required for absolute quantification. Equilibrium between the tracer in 
tissue and blood is achieved 40 min after commencing the radio-ligand infusion (Burger et al., 
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2010).We checked the dynamic uptake curve of each patient for suitability. Catheters were 
placed in the right antecubital vein for tracer injection prior to scanning. Subjects were 
scanned using [11C]ABP688 and a whole-body PET (Discovery VCT; GE Healthcare, 
Milwaukee, WI) in three-dimensional mode with an axial field of view of 14.6 cm and an in-
plane resolution of 7.0 mm. For attenuation correction, low-dose computed tomography was 
acquired before tracer injection. A total of 600–800 MBq of [11C]ABP688 in a 50-mL volume 
was administered using an infusion pump (half was given as a bolus over 2 min and the other 
half infused over the next 58 min). Image acquisition and reconstruction were performed as 
described earlier (Akkus et al., 2014; Ametamey et al., 2006; Deschwanden et al., 2011; 
Treyer et al., 2007), using the cerebellum as the reference region. Normalization of the images 
to MNI space was performed using averaged early frames image that resembles perfusion 
images using PMOD Fusion tool (Version 3.5). Transformation matrices were then applied to 
late frame images. Consistently we our previous studies, twelve standard regions of interest 
(ROIs) were included: 3 cortical (frontal, parietal, and temporal), 2 within the cingulate gyrus 
(anterior and posterior), 3 in the prosencephalon (caudate, putamen, and thalamus), 3 within 
the limbic system (medial orbitofrontal cortex [mOFC], amygdala, and medial temporal lobe), 
and a general grey-matter region. Analyses were conducted using PMOD (Version 3.5, 
PMOD Technologies, Switzerland).  
2.3. Statistical analysis 
SPSS 22 was used for statistical analysis.  Spearman's correlation analysis method was used  
for correlation assessments. To assess group effects we used  repeated measures general linear 
models when including all regions within one analysis or Student’s t-test for direct univariate 
comparisons and post-hoc tests. Furthermore, a general linear model was used to test for 
various factors with regards to effects in a region of interest. If required Bonferroni 
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corrections were applied considering non hypothesis guided multiple tests and were clearly 
stated in the text.. All reported p values are two-sided 
 
3. Results 
The clinical characteristics of the15 patients with schizophrenia and 15 age- and gender-
matched healthy subjects are shown in Table 1. All patients were stably medicated and their 
respective antipsychotic medications were transformed into chlorpromazine equivalents. All 
patients took atypical neuroleptics (risperidone, paliperidone, quetiapine, clozapine), except 
for one patient treated with flupentixol and two with an atypical combined with 
zuclopenthixol.  
We assessed differences in clinical characteristics between groups and other potential 
confounding factors. Age did not differ across the groups (t28 = 0.172, p > 0.86), and there 
was no significant age difference between male and female subjects in the total sample (t28 = 
−0.126, p = 0.9). The groups differed with respect to BDI (t28 = 5.365, p = 0.000); 
schizophrenia, 14.3 ± 9.0; healthy subjects, 1.7 ± 1.7) and BAI scores (t28 = 2.648, p = 0.013; 
schizophrenia, 7.4 ± 4.6; healthy subjects, 3.1 ± 4.2).  
As in Figure 1, we observed no significant difference in the mGluR5 DVR between those 
with schizophrenia and healthy subjects. The repeated measures general linear model using 
the 12 regions as repeated variables and group as factor revealed no between-subjects effects 
(F(28,1) = 0.11; p > 0.9). Even with gender, age, BDI, and BAI as potential covariates added to 
the above general linear model, there were no significant differences between the two groups 
(F(24,1) = 0.114; p = 0.738). Age as a covariate produced a rather high F-value but remained 
insignificant (F(24,1) = 4.24; p =0.051). Adding smoking status as a second factor to the model, 
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we found a significant difference between smokers and nonsmokers (F(22,1) = 185.632; p = 
0.000; 23.8% difference in DVR over all regions) which did not show an interaction with the 
diagnostic group (F(22,1) = 0.320; p = 0.578) in the same model. The covariate BDI became 
significant for between-subjects effects (F(22,1) = 8.019; p = 0.01) in this analysis but did not 
correlate with mGluR5 values. 
There was no correlation between the receptor systems for the prescribed neuroleptics and the 
mGluR5 DVR. There was a slightly significant correlation with chlorpromazine equivalents 
in some regions but this was not significant after Bonferroni correction. A partial correlation 
controlling for smoking status did not reveal any overall significance. The supplement 
includes more information on mGluR5 DVR and clinical variables, including treatment 
setting, extrapyramidal side effects, dose and duration of current antipsychotic medication 
(Figures S1-S6; Tables S1 and S2).  
 MGluR5 levels in the mOFC correlated with the medication dose in nonsmokers subgroup (r 
= 0.9, p =0.019). Also correcting for the non-significant correlation within the smoking 
patient group this effect stays significant (corrected significance level = 0.025). In Figure 2, 
we depict the distribution in this key region.  
Focusing on the same region, we identified a significant effect by testing interactions between 
gender differences, smoking and clinical status: between group and gender interaction we see 
a significant effect (F(22,1) = 8.706; p = 0.007), and a non-significant trend in the triple 
interaction (F(22,1) = 3.884; p = 0.061; see Figure 3). 
Neither education level nor current use of cannabis revealed a significant effect on the 
mGluR5 DVR (t-Test analysis). Within the schizophrenia group, the PANSS total score and 
subscales scores, BPS scores, BDI total score, BAI total score, age of onset, and illness 
duration did not correlate with mGluR5 DVR (for more details see supplementary material). 
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4. Discussion 
This is the first PET study to investigate mGluR5 DVR in individuals with schizophrenia and 
healthy controls. We did not find a difference in mGluR5 DVR between groups. In subjects 
with schizophrenia, we did not find associations between mGLuR5 DVR, symptom severity, 
or symptom dimensions. In both diagnostic groups, smoking was associated with a marked 
global reduction in mGluR5 DVR. In nonsmoking subjects with schizophrenia, we found a 
positive correlation between mGluR5 DVR in the mOFC and the use of mostly atypical 
antipsychotic drugs. In the same region, we found a trend for a triple interaction between 
group, gender, and smoking status. Most interesting was the interaction in nonsmokers 
between gender and the diagnostic group: schizophrenia was associated with higher mGluR5 
DVR in female subjects, but with lower mGluR5 DVR in male subjects (p < 0.05). This result 
is preliminary due to the small sample size, but revealed potential new insights, which should 
be followed up in further studies focusing on gender and smoking in schizophrenia. The 
finding is consistent with reports on gender-specific risk factors for smoking in schizophrenia 
(Johnson et al., 2010), and interactions between estradiol and mGluR5 in the pathogenesis of 
addiction (Peterson et al., 2015). 
Previously, associations have been found between schizophrenia and the mGluR5 gene, 
GRM5, and genes associated with mGluR5 such as those coding for Homer proteins, the 
postsynaptic density-95 gene, and the regulator of G protein signaling 4, RGS4 (Devon et al., 
2001; Matosin and Newell, 2013; Ting et al., 2012). The postmortem literature on mGluR5 in 
schizophrenia is ambiguous. The mRNA for mGLuR5 was variously increased in a specific 
layer and region of the prefrontal cortex (Ohnuma et al., 1998), decreased in individuals with 
schizoaffective disorders (Matosin and Newell, 2013), and unchanged in other studies (Fatemi 
et al., 2013; Matosin et al., 2015a; Ohnuma et al., 2000; Richardson-Burns et al., 2000; Volk 
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et al., 2010). Studies on mGluR5 protein expression in schizophrenia have identified 
increased (Matosin et al., 2015a), decreased (Fatemi et al., 2013), and normal protein levels 
(Corti et al., 2011; Fatemi et al., 2013; Gupta et al., 2005; Matosin et al., 2013). This 
disagreement may be due to differences between regions, schizophrenia subtypes, sample 
composition, antipsychotic use, smoking, sample size, and biochemical assays.   
Our finding that mGluR5 DVR did not differ between groups is consistent with the majority 
of studies using postmortem tissue. This may be due to the fact that the postmortem studies 
are subject to the same confounding factors as our imaging study. For instance, most 
postmortem studies did not examine mGluR5 in a cell-type specific manner or accounting for 
masked alterations for instance due to fast-spiking (GABA)-ergic interneurons. The 
hypothesis that mGluR5 is decreased in schizoaffective disorder would be consistent with our 
finding of decreased mGluR5 DVR in depression (Deschwanden et al., 2011). However, we 
did not find any association between mGluR5, depressive symptoms, or the BPS affect 
subscale in schizophrenia subjects.  
The strengths of our study include the matching of cases and controls for smoking status. In a 
previous study we found a marked global reduction in mGluR5 in smokers and recent ex-
smokers (average abstinence duration of 25 weeks) (Akkus et al., 2013). In a follow-up study 
we found normal mGluR5 DVR in long-term ex-smokers and a trend for a relationship 
between low mGluR5 DVR and the risk of relapse (Akkus et al., 2015). Together, these data 
suggest that the down-regulation of mGluR5 is a mechanism underlying nicotine dependence 
and the high risk of relapse in ex-smokers. It is not yet clear whether this effect is pathogenic 
or an unsuccessful compensatory mechanism. In this study, we found preliminary evidence 
for an interaction between smoking and gender, which is consistent with important gender-
specific factors in the pathogenesis of schizophrenia.   
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The majority of individuals with schizophrenia are smokers and have a smoking cessation rate 
of 10%–27%, compared with 43% for subjects without psychiatric conditions (Wing et al., 
2012). The vulnerability hypothesis proposes that common genetic and environmental factors 
explain the high comorbidity between schizophrenia and nicotine addiction (Chambers, 
2009). Dysfunction of the glutamatergic system may be a final common pathway increasing 
the risk of both conditions (Kalivas, 2009). Given growing evidence that smoking 
prospectively predicts risk for schizophrenia (Kendler et al., 2015), one might speculate that 
the marked global reduction of mGluR5 DVR in smokers constitutes a neurobiological risk 
factor for this severe psychiatric condition. For example, because mGluR5 and NMDA 
receptors are structurally and functionally closely connected, reduced mGluR5 signaling may 
contribute to NMDA receptor hypofunction that is thought to be a common final pathway of 
various schizophrenia symptoms including sensory deficits, general cognitive deficits, and 
impaired learning and memory (Kantrowitz and Javitt, 2010). 
The self-medication hypothesis posits that subjects with schizophrenia smoke to reduce 
symptoms, particularly negative and cognitive symptoms, and the side effects of antipsychotic 
drugs such as drug-induced Parkinsonism (Winterer, 2010). The positive correlation between 
mGluR5 and antipsychotic use that we found in nonsmokers seems to support the self-
medication hypothesis with regard to medication side effects. In haloperidol-treated patients 
with schizophrenia, the application of nicotine through transdermal patches reduced 
bradykinesia-rigidity (Yang et al., 2002). Because the majority of subjects included in our 
study used atypical antipsychotics, one might conclude that this nicotine effect is irrelevant. 
However, newer antipsychotics also produce extrapyramidal side effects, particularly when 
used in higher doses and as part of a combination treatment, although we could not show such 
a relationship in our sample. The association between smoking and low mGluR5 DVR might 
represent a mechanism underlying the improvement of extrapyramidal side effects through 
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nicotine consumption given that the specific pharmacological blocking of mGluR5 has 
emerged as one of the most attractive non-dopaminergic-based strategies in the management 
of motor symptoms in Parkinson’s Disease (Vallano et al., 2013). Previously, we reported on 
a positive correlation between anxiety-related symptoms and mGluR5 DVR (Akkus et al., 
2014). As a result, smoking in schizophrenia may also help to reduce some of the non-motor 
side effects of antipsychotics related to their effects on glutamate signaling. Our study was not 
large enough to address this possibility.  
Previous studies on the effects of antipsychotics on mGluR5 binding have been inconsistent. 
In rats, both haloperidol and sertindole increased mGluR5 mRNA (Iasevoli et al., 2010). 
However, another rat study did not find changes in mGluR5 protein expression following 
treatment with olanzapine and haloperidol (Matosin and Newell, 2013). In postmortem 
studies, no clear association between antipsychotic use and mGluR5 binding has been 
identified so far (Matosin et al., 2015a; Matosin et al., 2013). These data have to be 
interpreted with caution since the quality of data from postmortem studies is often 
questionable. 
In nonsmokers with schizophrenia, female subjects showed increased, and male subjects 
showed decreased mGluR5 DVR. An interesting study on prenatal chronic mild stress in rats 
demonstrated that stress-related changes in mGluR5 expression were sex-specific (Wang et 
al., 2015). Although the direction of change was opposite to our findings, both studies point to 
the potential importance of sex-specific factors in the development of chronic psychiatric 
conditions. The functional relationships between estrogen receptors and mGluR5 (Grove-
Strawser et al., 2010) may contribute to sex-specific glutamatergic dysfunction in 
schizophrenia.  
Several methodological limitations merit comment. Firstly, we oversampled the control group 
for smokers. In reality, individuals with schizophrenia might have lower mGluR5 binding 
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than nonpsychotic subjects because they smoke more frequently and more heavily (Wing et 
al., 2012), although many individuals with schizophrenia do not smoke and we did not find a 
correlation between the amount of nicotine consumption and mGluR5 DVR. Secondly, our 
samples were relatively small to demonstrate a negative finding. This is particularly important 
because there were important subgroups regarding mGluR5 DVR. However, the effect of 
smoking on mGluR5 is so strong and consistent across studies that an increase in sample size 
unlikely changed the results of this study. Thirdly, the cross-sectional design of this study 
without repeated assessments of mGluR5 DVR cannot investigate the potentially complex 
interplay between schizophrenia vulnerability, smoking, and antipsychotic use on mGluR5 
DVR. The relatively long illness duration might have influenced the results due to 
compensatory regulatory effects and long term medication effects. Fourthly, we did not 
exclude cannabis users because cannabis consumption is very common in schizophrenia and 
exclusion would have led to a markedly non-representative sample. Because only one non-
smoker was cannabis user and smoking had a very strong influence on mGluR5 DVR, we 
were not able to do more refined analyses on cannabis use. It may well be that cannabis or 9-
THC does not directly act on dopamine firing but indirectly by altering glutamate 
neurotransmission, which may have confounded the results of this study. Fifthly, individuals 
with schizophrenia were treated with antipsychotic medication, which may be have been an 
important confounding factor. Our analyses on medication did not show associations between 
chlorpromazine equivalents and mGluR5 DVR, which may be due to the fact that these 
equivalents adjust dosages regarding dopaminergic effects but not the influence on the 
glutamatergic system. Finally, in order to avoid potentially painful arterial cannulation, we 
used a bolus-infusion technique, normalizing PET images to the cerebellar radioactivity 
concentration. The normalization itself is never perfect and small regions can be incorrectly 
normalized, especially as the functional region outline might not be identical to the 
anatomical position of a region. We based our reference tissue method on the assumption that 
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mGluR5 levels are very low in the cerebellum compared with predefined ROIs in other brain 
areas (Elmenhorst et al., 2010). Various types of evidence support this assumption, including 
in vitro and in vivo studies on binding to ABP688 in the cerebellum (Ametamey et al., 2007; 
Elmenhorst et al., 2010), a study on cerebellar mGluR5 protein expression in postmortem 
tissue (Deschwanden et al., 2011), previous PET studies (Barret et al., 2010), and studies on 
cerebellar mRNA expression (Berthele et al., 1999; Daggett et al., 1995; Malherbe et al., 
2002).  
In conclusion, we showed that mGluR5 DVR in the brains of subjects with schizophrenia is 
not different from that of healthy controls. As in controls, smoking was associated with a 
marked global reduction in mGluR5 DVR. This may be of clinical importance since 
antipsychotic drugs such as clozapine appear to have indirect effects on mGluR5 signaling 
(Gray et al., 2009). This study provides promising leads for elucidating the high comorbidity 
between schizophrenia and tobacco addiction. One may speculate that downregulation of 
mGluR5 in smokers is a risk factor for schizophrenia. Alternatively, smoking may counteract 
the potential upregulation of mGluR5 by antipsychotic drugs to counteract medication side 
effects. Finally, this study has revealed important sex-specific variations in the glutamatergic 
dysfunction underlying schizophrenia. Future mGluR5 imaging studies should include 
younger patients with a shorter illness duration to reduce potentially confounding factors such 
as long-term medication and examine the role of mGluR5 in early stages of the illness.  
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Figure legends 
 
Figure 1. The distribution of all DVRs over all regions in both groups and their smoking 
status. Smoking status revealed strong differences, while the overlap between clinical groups 
was high. 
 
Figure 2. The figure shows the effect of medication dose (converted in to chlorpromazine 
equivalents) on mGluR5 levels in the mOFC region of nonsmokers. All patients were 
medicated, and the medication level of zero refers to mGluR5 reference values for the control 
group. There was no correlation between medication equivalent levels and mGluR5 DVR in 
smokers.  
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Table 1. Clinical characteristics of study groups  
Clinical characteristic Patients with 
schizophrenia 
(n = 15) 
 Control 
group 
(n = 15) 
 
Gender (f/m) 6/9  6/9  
Smoker, n (f/m) 9 (3/6)  9 (5/4)  
Cigarette consumption (d) 25.8 (7.6)  18.9 (4.3)  
Years of consumption 17.9 (10.9)  15.4 (7.9)  
Age (years) 38.2 (10.7)   37.5 (10.6)  
Onset of illness (age in years) 22.6 (7.0)    --  
Duration of illness (years) 15.6 (11.6)    --  
Medication (average dose mg/  
n number of patients) 
Clozapin(470/4) 
Quetiapine(410/5) 
Paliperidon(8/2) 
Aripiprazol(10/2) 
Risperidon(2/1) 
 
  --  
Cannabis users 5  0  
Highest educational qualification: 
High school uncompleted 
High school, completed 
College, completed 
Academic completed 
 
5 
14 
1 
- 
  
- 
13 
- 
2 
 
Subgroups Nonsmoker  
(n = 6) 
Smoker  
(n = 9) 
Nonsmoker 
(n = 6) 
Smoker 
(n = 9) 
Beck Anxiety Inventory score 8.8 6.4 1 4.6 
Beck Depression Inventory score 12.2 15.8 1.3 1.9 
PANSS Positive 14.9 (4.1) 13.2 (2.4) -- -- 
PANSS Negative 17.7 (8.1) 20.8 (9.1) -- -- 
20 
 
PANSS General 27.6 (11.9) 35.0 (8.3) -- -- 
PANSS Total score 62.7 (20.1) 69 (18.5) -- -- 
The data are displayed as means (SD), unless indicated otherwise. 
n refers to the number of participants within this category.  
 
 
 
